The company discussed in today’s article is a potential leader in a burgeoning field that the author declares “has the potential to revolutionize medicine in potentially the same way that genomics has”: proteomics. Specifically, this company operates as a diagnostics company in the proteomics space – and its technology has the potential to disrupt the traditional approach to proteomics and tackle next-generation proteomics. For more on this speculative investment, CLICK HERE.
A Speculative Stock For What May Be “The Next Big Thing To Sweep Through Biotech”
